101623-69-2

Basic information

• Product Name: Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester
• Synonyms: Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester;1-Chloroethyl (4-nitrophenyl) carbonate;1-Chloroethyl p-nitrophenyl carbonate
• CAS NO: 101623-69-2
• Molecular Formula: C₉H₈ClNO₅
• Molecular Weight: 245.61652
• Mol File: 101623-69-2.mol
• Article Data: 21

Chemical Properties

• Melting Point: 71.0-71.7 °C(Solv: hexane (110-54-3))
• Boiling Point: 359.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.415±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester(101623-69-2)
• EPA Substance Registry System: Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester(101623-69-2)

Safety Data

• Hazardous Substances Data: 101623-69-2(Hazardous Substances Data)

Usage

General Description

Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester is a chemical compound with the molecular formula C9H8ClNO5. It is a derivative of carbonic acid and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Carbonic acid 4-nitro-phenyl ester 1-chloro-ethyl ester is known for its ability to act as a reagent in organic chemistry reactions, particularly in the formation of carbon-carbon and carbon-oxygen bonds. It is also used as a precursor in the production of various esters, which are important in the fragrance and flavor industry. Additionally, this compound has potential applications in medicinal chemistry and drug discovery. However, it is important to handle this chemical with caution due to its potentially hazardous properties.

Upstream product

• 100-02-7 4-nitro-phenol 
• 50893-53-3 carbonochloridic acid 1-chloro-ethyl ester 

Downstream Products

• 101623-68-1 1-{[(4-nitrophenoxy)carbonyl]oxy}ethyl acetate 
• 182747-25-7 1-(trimethylacetoxy)ethyl p-nitrophenyl carbonate 
• 1034191-21-3 1-(((4-nitrophenoxy)carbonyl)oxy)ethyl benzoate 
• 1034191-20-2 C₂₅H₂₇NO₉ 
• 1321458-96-1 1-((4-nitrophenoxy)carbonyloxy)ethyl-2, 2-dimethyl-3-(nitrooxy)propanoate 
• 1321458-86-9 1-((4-nitrophenoxy)carbonyloxy)ethyl 2-(2-(nitrooxy)ethoxy) acetate 
• 194995-47-6 1-[[(4-nitrophenoxy)carbonyl]oxy]-2-methylpropionic acid ethyl ester 
• 478296-69-4 1-iodoethyl 4-nitrophenyl carbonate 

Relevant articles and documents

Repeated dosing with NCX1404, a nitric oxide-donating pregabalin, re-establishes normal nociceptive responses in mice with streptozotocin-induced painful diabetic neuropathy

NCX1404 [(3S)-5-methyl-3-(((1-(4-(nitrooxy)butanoyloxy)ethoxy) carbonylamino) methyl)hexanoic acid] is a novel nitric oxide (NO)-donating pregabalin that is readily absorbed and processed in vivo to pregabalin and NO. We determined the antiallodynic response of NCX1404 after acute or after 7, 14, and 21 days of repeated daily oral dosing in mice with streptozotocin (STZ)-induced painful diabetic neuropathy (PDN). Pregabalin and its combination with the NO donor isosorbide mononitrate (ISMN) were used for comparison. The blood levels of pregabalin and nitrites, used as surrogate marker of NO release, after NCX1404 or pregabalin dosing were monitored in parallel experiments using liquid chromatography with tandem mass spectrometry (LC-MS/MS). NCX1404 and pregabalin resulted in similar pregabalin levels as it was their antiallodynic activity after acute dosing in STZ mice. However, NCX1404 resulted in disease-modifying properties when administered daily for 21 days, as indicated by the time- and dose-dependent reversal of STZ-induced mechanical allodynia (paw withdrawal threshold [PWT]Veh-21d = 1.3 v 0.15 g for vehicle; PWTNCX1404-21d = 1.4 ± 0.5 g, 2.9 ± 0.2 g? and 4.1 ± 0.2 g?, respectively for 19, 63, and 190 μmol/kg, oral gavage [PO] of NCX1404; ?P, 0.05 versus vehicle). This effect was not shared by pregabalin at equimolar doses (190 μmol/kg, PO, PWTPregab-21d = 1.4 ± 0.1 g?, ?P Veh-7d= 1.7 ± 0.16 g; PWTISMN-7d = 3.9 ± 0.34 g?; PWTPregab-7d = 1.3 ± 0.07 g; PWTISMN+pregab-7d = 3.8 ± 0.29 g?; ?P, 0.05) but not at later time points. The long-term effect of NCX1404 was independent of residual drug exposure and lasted for several days after the treatment was stopped. In summary, like pregabalin, NCX1404 is an effective antiallodynic agent. Differently from pregabalin, repeated dosing of NCX1404 re-established normal nociceptive responses in STZ-induced PDN in mice.

AZETIDINE DERIVATIVE, AND PRODRUG THEREOF

An object of the present invention is to provide a compound useful as a therapeutic or prophylactic drug for a disease involving the immune system, by suppressing a function of immune cells by suppressing proliferation of activated T cells or suppressing production of interferon alpha (IFN-α) by activated plasmacytoid dendritic cells (pDC), particularly an autoimmune disease such as systemic lupus erythematosus (SLE) and lupus nephritis in SLE patients. The present invention provides a compound represented by general formula (I) : [wherein X, R1, R2, R3, R4, R5 and R6 are as described in the description], or a pharmaceutically acceptable salt thereof.

Pharmaceutical composition for the treatment or prevention of stroke and systemic embolism

The present invention relates to a prodrug useful for treating or preventing a stroke and systemic embolism and suitable for being effectively used in the oral delivery of dabigatran, and to a compound represented by chemical formula 1, a pharmaceutically acceptable salt thereof, and a hydrate thereof or a solvate thereof. The compound represented by the chemical formula 1, the pharmaceutically acceptable salt thereof, and the hydrate thereof or the solvate thereof are useful for treating or preventing a stroke and systemic embolism, and is suitable for being effectively used in oral delivery since the absorption rate, that is, bioavailability of dabigatran is improved.(AA) DSC curve of dabigatran pivoxyl (+)-(1S)- campo-10-sulfonateCOPYRIGHT KIPO 2015